George A. Scangos - Feb 22, 2024 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Director
Signature
/s/ Sung Lee, Attorney-in-Fact
Stock symbol
VIR
Transactions as of
Feb 22, 2024
Transactions value $
-$307,259
Form type
4
Date filed
2/26/2024, 07:30 PM
Previous filing
Feb 20, 2024
Next filing
Mar 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Sale -$101K -10K -7.13% $10.05 131K Feb 22, 2024 Direct F1
transaction VIR Common Stock Sale -$207K -17.7K -13.56% $11.65 113K Feb 26, 2024 Direct F2, F3
holding VIR Common Stock 1.75M Feb 22, 2024 See footnote F4
holding VIR Common Stock 1.75M Feb 22, 2024 See footnote F5
holding VIR Common Stock 33.6K Feb 22, 2024 See footnote F6
holding VIR Common Stock 180K Feb 22, 2024 See footnote F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 20, 2023.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.21 to $11.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The shares are held in the name of the George A Scangos 2023 Annuity Trust, of which the reporting person and his spouse are Trustees.
F5 The shares are held in the name of Leslie Wilson 2023 Annuity Trust, of which the reporting person and his spouse are Trustees.
F6 The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011.
F7 The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees.